Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

In a recent study published in Life Metabolism, researchers at Fudan University report that even after stopping the anti-obesity drug tirzepatide, ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

Weight loss jabs will be given to 3,000 people in a trial to explore whether they can get people back into work, The i Paper understands. A five-year trial of the weight loss drug tirzepatide in ...

Eli Lilly and Company is conducting a clinical study titled ‘Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage trials of obeldesivir. | Gilead has blamed the low rate of respiratory ...

Here’s the unglamorous truth that I’m hesitant to admit: The price tag is a commitment. Tirzepatide isn’t covered by insurance unless you qualify under certain medical conditions — diabetes, for ...

Based on that criterion, ten out of 12 people (83%) in a new clinical trial were cured of their diabetes one year after receiving an advanced stem cell therapy.

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with overweight or obesity, outperforming liraglutide and placebo. Brain ...

Anthropic wins ruling on AI training in copyright lawsuit but must face trial on pirated books The Anthropic website and mobile phone app are shown in this photo, in New York, July 5, 2024.